Colpan Leyla, Gur Ali, Cevik Remzi, Nas Kemal, Sarac Aysegul Jale
Department of Biochemistry, Medical Faculty of Dicle University, Diyarbakir, Turkey.
Maturitas. 2005 Jul 16;51(3):246-53. doi: 10.1016/j.maturitas.2004.07.013.
A double-blind, randomized, placebo-controlled trial was conducted in women with postmenopausal osteoporosis to evaluate effects on biochemical markers and urinary excretion of zinc (Zn) of calcitonin therapy.
Patients were required to have a bone mineral density (BMD) of 2.5 S.D. or more below the young adult mean either at the postero-anterior lumbar spine or at the femoral neck. Subjects were eligible for our study if they were 50 years or older, with at least 5 years of menopause, and in good general health as determined by medical history and a routine clinical blood analysis. The patients were randomly assigned to receive intranasal salmon calcitonin (200 IU/day; 50 patients) or placebo (50 patients). All patients received supplemental calcium (1000 mg/day). Additionally, 40 age-matched, demographically similar, healthy postmenopausal women were also selected as controls. Measurements of cross-linked N-telopeptides of type I collagen (uNTx), osteocalcin (sOC), and urinary zinc concentration were done. All parameters were measured before therapy and again after 1, 3 and 6 months.
After 3 and 6 months of treatment, a higher decrease of most indices was observed in the calcitonin group. A statistically significant decrease occurred in the levels of sOC, uNTx and uZn after 3 and 6 months in patients receiving calcitonin therapy (P<0.05). Levels of sOC and uNTx in calcitonin group were significantly different after 3 and 6 months from both placebo and baseline values of calcitonin group (P<0.05). Levels of sOC, uNTx and uZn decreased about 40, 46 and 37%, respectively, in calcitonin group at 6 months after the start of treatment.
Our study suggests that values of uNTx, uZn and sOC were significantly lower in the patient group than those in control group and in postmenopausal women with osteopororsis, calcitonin reduces the concentrations of uNTx, uZn and sOC.
在绝经后骨质疏松症女性中进行一项双盲、随机、安慰剂对照试验，以评估降钙素治疗对生化指标及锌（Zn）尿排泄的影响。
患者需在后前位腰椎或股骨颈处的骨密度（BMD）比年轻成人平均值低2.5个标准差或更多。如果受试者年龄在50岁及以上，绝经至少5年，且根据病史和常规临床血液分析确定总体健康状况良好，则符合本研究条件。患者被随机分配接受鼻内鲑鱼降钙素（200 IU/天；50例患者）或安慰剂（50例患者）。所有患者均接受补充钙（1000 mg/天）。此外，还选择了40名年龄匹配、人口统计学特征相似的健康绝经后女性作为对照。进行了I型胶原交联N-端肽（uNTx）、骨钙素（sOC）和尿锌浓度的测量。所有参数在治疗前以及治疗1、3和6个月后再次测量。
治疗3个月和6个月后，降钙素组大多数指标的下降幅度更大。接受降钙素治疗的患者在治疗3个月和6个月后，sOC、uNTx和uZn水平出现统计学显著下降（P<0.05）。降钙素组在治疗3个月和6个月后的sOC和uNTx水平与安慰剂组及降钙素组的基线值均有显著差异（P<0.05）。治疗开始6个月后，降钙素组的sOC、uNTx和uZn水平分别下降了约40%、46%和37%。
我们的研究表明，患者组的uNTx、uZn和sOC值显著低于对照组，且在绝经后骨质疏松症女性中，降钙素可降低uNTx、uZn和sOC的浓度。
